The International Society of Blood Transfusion working party on hemovigilance in collaboration with the International Haemovigilance Network and AABB produced new reporting criteria in 2018. Patients classified with TACO should have acute onset or worsening respiratory distress or evidence of pulmonary edema, or both during or up to 12 hours after transfusion. They should have at least 3 of the following characteristics:
Acute or worsening respiratory distress in the absence of other causes
Evidence of acute or worsening pulmonary edema
Evidence of unanticipated cardiovascular system changes
Evidence of fluid overload
Changes in a relevant biomarker e.g. elevation in natriuretic peptide levels, N-terminal to greater than 1.5 times the pre-transfusion value.
Differential diagnosis
TACO and TRALI are both respiratory complications following a transfusion. TACO and transfusion related acute lung injury are often difficult to distinguish in the acute situation. TACO is usually associated with hypertension and responds well to diuretics, TRALI is often associated with hypotension and diuretics have a minimal effect. A normal natriuretic peptide level post-transfusion is seen with TRALI but not with TACO.
Prevention
Transfusion associated circulatory overload is prevented by avoiding unnecessary transfusions, closely monitoring patients receiving transfusions, transfusing smaller volumes of blood at a slower rate, and considering the use of diuretics. A pre-transfusion TACO checklist can be used to assess patients' risk of developing TACO.
Management
If TACO is suspected stop the transfusion. Treat with oxygen, diuretics, and other treatments for cardiac failure.
Occurrence
It is difficult to determine the incidence of TACO, but its incidence is estimated at about one in every 100 transfusions using active surveillance, and in one in every 10000 transfusions using passive surveillance. TACO is the most commonly reported cause of transfusion-related death and major morbidity in the UK, and second most common cause in the USA. The risk increases with patients over the age of 60, patients with cardiac or pulmonary failure, renal impairment, hypoalbuminemia or anemia.